NeuroSense Therapeutics Ltd. (NRSN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Herzliya, Israel. The current CEO is Alon Ben-Noon.
NRSN has IPO date of 2021-12-09, 17 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $18.01M.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
